PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment
PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment
PharmaTher收到美國專利補貼通知，該專利涵蓋治療帕金森氏症和運動障礙的氯胺酮
Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB:PHRRF) has been granted a Notice of Allowance by the U.S. Patent and Trademark Office (USPTO) for its "Compositions and Methods for Treating Motor Disorders" patent, intended to cover potential ketamine treatment of Parkinson's disease and motor disorders causing involuntary or uncontrollable body actions.
氯胺酮藥品供應商PharmaTher控股有限公司(場外交易代碼：PHRRF)已被授予一項美國專利商標局(USPTO)的補貼通知為其“治療運動障礙的組合物和方法”申請專利，意在涵蓋潛在的氯胺酮治療帕金森病和運動障礙導致不自主的或不能控制的身體動作。
PharmaTher signed an exclusive license agreement with the University of Arizona to develop and commercialize the patent in August 2020. The results from the clinical study of ketamine for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's would be made available in late-Q3 2022.
PharmaTher與該公司簽署了獨家許可協議亞利桑那大學在2020年8月開發該專利並將其商業化。氯胺酮治療帕金森氏症患者左旋多巴誘導的運動障礙(LID)的臨牀研究結果將於2022年第三季度末公佈。
More...
更...
登入免費觀看全文
登入/註冊